HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MacGregor, E. A. Articles by Aspinall, L. Search for Related Content PubMed PubMed Citation Articles by MacGregor, E. A. Articles by Aspinall, L. Related Collections Migraine Related Article

Predicting menstrual migraine with a home-use fertility monitor

From The City of London Migraine Clinic (Dr. MacGregor, A. Frith); Departments of Gynaecology and Sexual Health (Dr. MacGregor), St. Bartholomew’s Hospital, London; Unipath Limited (Dr. Ellis), Bedford; and Unilever Research (L. Aspinall), Sharnbrook, UK.

Address correspondence and reprint requests to Dr. E.A. MacGregor, The City of London Migraine Clinic, 22 Charterhouse Square, London, EC1M 6DX, UK; e-mail: anne.macgregor{at}bartsandthelondon.nhs.uk

A home-use fertility monitor was used to time perimenstrual prophylaxis in 27 women with menstrual or menstrually related migraine. Cycle length variability was mostly caused by follicular phase variability; the postovulatory luteal phase was relatively constant. The monitor accurately identified ovulation in >90% of cycles, enabling prediction of menstruation and precise timing of perimenstrual prophylaxis. Ninety-seven percent of women found the monitor useful in predicting menstrual migraine attacks.

Supported by a grant from Unipath Limited. E.A.M. has received consulting fees from Unipath Limited. E.A.M. and A.F. have received funding from Unipath to attend an international meeting. The City of London Migraine Clinic has received research funds from Unipath Limited. ClearPlan Fertility Monitors were supplied by Unipath Limited, and Estreva estradiol gel and matching placebo were supplied by Merck-Theramex.

Received April 26, 2004. Accepted in final form September 21, 2004.

Related Article

February 8 Highlights
Neurology 2005 64: 404-405. [Full Text] [PDF]

This article has been cited by other articles:

				E. A. MacGregor, A. Frith, J. Ellis, L. Aspinall, and A. Hackshaw Prevention of menstrual attacks of migraine: A double-blind placebo-controlled crossover study Neurology, December 26, 2006; 67(12): 2159 - 2163. [Abstract] [Full Text] [PDF]